Luspatercept: A Challenge to Erythropoietin and Its Role in Boosting QOL in MDS
Targeted Therapies in Oncology: What are the advantages/disadvantages for choosing luspatercept vs an erythropoietin agent for initial therapy? A: SOLLY CHEDID, MD: Luspatercept has some significant advantages. One significant advantage is the response …